Anthropic sues the Pentagon to overturn the national security blacklist

robot
Abstract generation in progress

Investing.com – Anthropic filed a lawsuit on Monday to try to prevent the Pentagon from listing it on the national security blacklist. This artificial intelligence lab’s dispute with the U.S. military over restrictions on its technology use has escalated further.

The Pentagon designated Anthropic as an official supply chain risk on Thursday, restricting the use of its technology. According to sources, the technology had previously been used in military operations in Iran.

Anthropic stated in the lawsuit that this designation is illegal and infringes on its free speech and due process rights. The company filed a complaint in a federal court in California seeking to have the designation overturned and to prevent federal agencies from enforcing the decision.

“These actions are unprecedented and illegal. The Constitution does not permit the government to abuse its vast power to punish a company for protected speech,” Anthropic said.

Last week, Secretary of Defense Pete Hegseth designated Anthropic as a national security supply chain risk after the startup refused to remove restrictions on its AI’s use in autonomous weapons or domestic surveillance.

This designation poses a threat to Anthropic’s business with the government and could influence how other AI companies negotiate restrictions on the military use of their technology. CEO Dario Amodei clarified on Thursday that the designation is “narrow in scope,” and companies can still use their tools in projects unrelated to the Pentagon.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments